ArticleEndocrinology2025
SALL1 Is an Orchestrator of Uterine Receptivity in Part via Titration of Estrogen Signaling.
Article in Endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
SALL1 is a critical regulator of embryonic development across a wide swath of tissues, including vital organs, but little is known about its function in adult tissues. Recent work from our group demonstrates that SALL1 is involved in urogenital development. This study delineates the role of SALL1 transcription factor in the adult reproductive system by demonstrating its requirement at multiple levels of uterine function during the implantation phase of early pregnancy. By generating a conditional knockout mouse model of Sall1 exclusively in female reproductive organs, it is demonstrated here that SALL1 is independently required both in the uterine luminal epithelium for the attachment of competent blastocysts to the uterine wall and in the uterine stroma for the process of decidualization, another prerequisite for pregnancy success. This robust, multitissue-layer requirement for SALL1 across multiple stages in the process of implantation makes it a newly identified regulator of early pregnancy. Here, it is shown that loss of SALL1 causes misexpression of estrogen receptor α during the window of implantation, and subsequent pathological deregulation of multiple estrogen response genes whose tight titrations are prerequisites of pregnancy. RNA sequencing of independent knockout uterine compartments at multiple timepoints, and chromatin immunoprecipitation sequencing to identify direct transcriptional targets, elucidated multiple powerful regulatory pathways downstream of SALL1. Importantly, the use of a selective estrogen receptor antagonist, fulvestrant, at a precise timepoint and dose, offers a partial rescue of embryo attachment to the uterine luminal epithelium, further demonstrating that SALL1 is upstream of estrogen receptor α during implantation phase signaling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.